Kevin, the "odds ratio" debate is something that shorts have been pushing. The company already said that using ADAS-Cog measure that progression is slowed by 45%. Note that this is never debated here. The odds ratio is used only with respect to significantly improved patients. There doesn't have to be a single improved patient - even though in this trial there clearly were. Look at the recent Biogen/Eisai data - there were no improvers that I saw but the drug was approved.
News 
Market Data 
Discover 
